tanfanercept
Recombinant proteinexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02717208)
Timeline
Indications
Studied for
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594387 ↗
Also known as
- hl036
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05109702 | Phase 3 | Nov 18, 2021 | Daewoong Pharmaceutical Co. LTD., HanAll BioPharma Co., Ltd. |
| NCT04633213 | Phase 3 | Dec 1, 2020 | Harbour BioMed Co. Ltd., Xiamen University |
| NCT04092907 | Phase 2 | Mar 22, 2019 | Harbour BioMed Co. Ltd., Shandong Eye Institute |
| NCT03846453 | Phase 3 | Mar 10, 2019 | Daewoong Pharmaceutical Co. LTD., HanAll BioPharma Co., Ltd. |
| NCT03334539 | Phase 2 | Nov 5, 2017 | Andover Eye Associates, HanAll BioPharma Co., Ltd. |
| NCT02717208 | Phase 1 | Feb 1, 2016 | HanAll BioPharma Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HanAll BioPharma Co., Ltd. | For profit | 4 | 4 | 3 | 2016 |
| Daewoong Pharmaceutical Co. LTD. | For profit | 2 | 0 | 1 | 2019 |
| Harbour BioMed Co. Ltd. | For profit | 2 | 2 | 2 | 2019 |
| Andover Eye Associates | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Shandong Eye Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Xiamen University | Academic/Hospital | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1